Abstract
COVID-19 is a viral disease caused by SARS-CoV-2 that compromises the host immune response in severe cases, promoting a hyperinflammation that results in acute lung injury and multiple organs failure. In this context, patients presenting with immune-related diseases, such as Crohn’s disease, affected by COVID-19, may have an uncertain prognosis. We report on a case of a young female patient with a severe Crohn’s disease that presented with COVID-19 pneumonia and a favorable outcome even maintaining the use of adalimumab, TNF – alpha inhibitor and prednisone. This case raises the hypothesis that aside from prednisone, TNF-α inhibitors such as adalimumab could be used to stop the progression to COVID-19 complications by blocking the TNF-alpha-driven inflammatory process that occurs in severe COVID-19.
【초록키워드】 COVID-19, SARS-CoV-2, severe COVID-19, Prognosis, Pneumonia, progression, outcome, acute lung injury, Host immune response, hyperinflammation, female, Patient, severe cases, Alpha, Prednisone, viral disease, inhibitor, disease, TNF-α, TNF, Hypothesis, inflammatory process, raise, affected, caused, occur, presenting, COVID-19 complication, immune-related diseases, multiple organ, with COVID-19, 【제목키워드】 COVID-19, outcome, Case report, disease,